VCAM-targeted delivery of recombinant CD39 to the endothelium is antithrombotic, antiinflammatory and ameliorates ischaemia reperfusion injury. [ 2015 - ]

Research Grant

Researchers: Prof Harshal Nandurkar (Principal investigator) ,  Prof Karen Dwyer ,  Prof Peter Cowan

Brief description Blockage of arteries with clots leads to heart attacks and strokes. Reestablishment of blood supply by clot-busting drugs or mechanical interventions paradoxically causes further organ injury. This is due to toxic chemicals generated by inflammatory processes and free oxygen radicals. We have created an unique drug that selectively targets blood vessels that are injured by process. The drug will deliver blood-thinning activity and reduce inflammatory stress selectively at the site of need.

Funding Amount $603,813.00

Funding Scheme Project Grants

Notes Standard Project Grant